1.  Background
 
 DIL Limited (''the Company'') is in the business of renting properties,
 motion film production and distribution and in treasury operation. The
 Company also has strategic investments in subsidiary / associates
 companies primarily dealing in manufacturing of bulk drugs and contract
 research services and providing services of sporting and health
 awareness/ education activities.
 
 2. (a) During the previous year, the Company has executed a Share
 Purchase and a Shareholder''s Agreement (Agreements) on August 31, 2009
 with Evotec AG and transferred 2,54,94,000 equity shares of Rs. 2/-
 each. i.e. 70% of the paid up equity share capital of Evotec (India)
 Pvt. Ltd. (EIPL) (formerly known as Research Support International
 Private Limited (RSIPL)) for a consideration of Rs. 1,117.71 Lakhs, as
 a result of which w.e.f. September 1, 2009 EIPL and it''s wholly owned
 subsidiary Evotec RSIL Limited (ERL) are no longer subsidiaries of the
 Company. Accordingly, the Company''s interest in EIPL/ERL has been
 accounted as “Interest in Associate Company” in the consolidated
 financial statements.
 
 During the current year, the Company has received an earn out of Rs.
 413.55 Lakhs based on achievement of “ Earn Out Revenue” during the
 twelve months period ending on 31st August,2010 as per the terms
 stipulated in the aforesaid agreement.
 
 (b) During the current year, the Company agreed with its subsidiary -
 Fermenta Biotech Ltd. (''FBL'') to convert the 7,00,000 redeemable non
 convertible preference shares of Rs. 10. each together with share issue
 premium of Rs. 90.  each invested in FBL to Redeemable convertible
 preference shares and waived the additional premium that was due
 pursuant to the preference share issue document. Subsequent to this,
 these preference shares have been converted into 70,00,000 equity
 shares of Rs. 10 each at face value of FBL.
 
 (c) During the current year, the Company along with its subsidiary
 Fermenta Biotech Limited (FBL) has executed agreement with Evolence
 India Life Sciences Fund LLC (EILSF). Accordingly transaction was
 completed on January 17, 2011, whereby EILSF has acquired 21.05% Equity
 Capital of FBL through sale of 19,15,036 FBL equity shares by the
 Company to EILSF and issue of an equal number of fresh equity shares by
 FBL to EILSF at a price of Rs. 104.44 per equity share of Rs. 10 each.
 
 (d) During the current year, the Company has invested Rs. 225 Lakhs for
 15,96,892 equity shares of Rs. 10 each of Health and Wellness India
 Pvt. Ltd (HWIPL) Bangalore. HWIPL is in the business of providing
 services on sporting activities, health awareness and health education.
 With the aforesaid investment, Company holds 30.30% Equity Capital of
 HWIPL.  Accordingly, the Company''s interest in HWIPL has been accounted
 as “ Interest in Associate Company” in the consoli- dated financial
 statements.
 
                                                March 31,   March 31,
                                                    2011        2010
                                                  Rs. in      Rs. in 
                                                   Lakhs       lakhs  
 
 
 3.(b) Contingent liabilities, including            1.12       16.29 
 amounts  not provided for pertaining to 
 excise duty, sales tax and service 
 tax matters in respect of earlier years 
 for which appeals are pending before 
 appropriate authorities.  Future cash 
 outflows in respect of this contingent
 liabilities are determinable only on 
 receipt of judgments pending at various 
 forums / authorities.
 
 (c) Company has invested an aggregate of Rs. 188.51 Lakhs in VasKo
 Glider s.r.o. Czechoslovakia, a joint venture. Out of the above, Rs.
 1.96 Lakhs (Czech Koruna 1 Lakh) is towards basic capital and Rs.
 186.55 Lakhs (Czech Koruna 95.24 Lakhs) is towards voluntary additional
 contribution to capital. VasKo Glider is involved in manufacture of
 wheelchairs based on Levitation Movement Technology, acquired from the
 joint venture partner under the Technology transfer agreement with
 effect from March 18, 2005 and the patent of which is registered in
 Czechoslovakia in the name of the joint venture partner. The joint
 venture partner has applied for registration of patent in various
 countries and the same has been registered in USA, India and Australia.
 
 4.  Related party disclosures
 
 a.  Parties where control exists
 
 Mr. Krishna Datla - Managing Director, Party controlling holding
 company.
 
 Holding company
 
 DVK Investments Private Ltd
 
 Subsidiaries
 
 1.  Aegean Properties Ltd.
 
 2.  CC Square Films Limited (w.e.f. December 27, 2010)
 
 3.  Fermenta Biotech Ltd.
 
 4.  Fermenta Biotech (UK) Ltd. (100% subsidiary of Fermenta Biotech
 Ltd.)
 
 5.  G. I. Biotech Private Ltd. (62.50% subsidiary of Fermenta Biotech
 Ltd.) *
 
 6.  Evotec (India) Pvt. Ltd. (formerly known as Research Support
 International Private Limited upto August 31, 2009)
 
 7.  Evotec – RSIL Ltd. (subsidiary of Research Support International
 Private Limited) upto August 31, 2009 merged with Evotec (India)
 Private Ltd w.e.f. January 1, 2010 #
 
 b.  Other related party relationships where transactions have taken
 place during the year
 
 Fellow Subsidiary
 
 VM Cafe de Art Private Ltd.
 
 Key Management Personnel
 
 1.  Mr. Krishna Datla - Managing Director
 
 2.  Mr. Satish Varma - Executive Director (upto May 31, 2010)
 
 c.  Joint Venture 
 
 VasKo Glider s.r.o. **
 
 d.  Associates
 
 1.  Evotec (India) Pvt. Ltd .(formerly known as Research Support
 International Private Ltd.) (w.e.f. September 1, 2009)
 
 2.  Evotec RSIL Ltd. (subsidiary of Evotec (India) Pvt. Ltd.) (w.e.f.
 September 1, 2009) merged with Evotec (India) Private Ltd w.e.f.
 January 1, 2010 #
 
 3.  Health and Wellness India Private Ltd (w.e.f. March 15, 2011)
 
 e.  Related party relationship is identified by the Company on the
 basis of available information
 
 8. Employee Benefits
 
 ix) a) The discount rate is considered based on market yield on
 government bonds having currency and terms consistent with the currency
 and terms of post-employment benefit obligations.
 
 b) Expected rate of return on assets assumed by the Insurance Company
 is generally based on their investment pattern as stipulated by the
 Government of India.
 
 c) The estimates of rate escalation in salary considered in the
 actuarial valuation take in to account inflation, seniority promotion
 and other relevant factors including supply demand in the employment
 market.
 
 d) The Company is expected to contribute to the Gratuity fund during
 2011-12 Rs. 1.50 Lakhs (2010- Rs. Nil during 2010-11).
 
 9.  Previous year''s figures have been regrouped wherever necessary.